Long-term use of unfractioned heparin data has been associated with a 2.2—5% incidence of heparin-induced osteoporotic fracture, but for low-molecular-weight heparin (LMWH) data is scarce and there is lack of clarity of the risks of osteoporosis and osteoporotic fractures. In this paper we review the differential diagnosis of osteoporosis and osteoporotic fractures, and we conduct a systematic review of all related cases from case reports and trials. Two new cases of possible LMWH-induced osteoporosis are also presented and the difficulties in making the diagnosis are highlighted. The authors conclude that, until large clinical trials are designed to investigate pre- and post-treatment bone density and to compare different dosages of LMWH effect on the bone density in different patient groups, no safe conclusions can be made.
Greer I., Hunt BJLow molecular weight heparin in pregnancy: current issues. Br J Haematol2005; 128: 593-601.
2.
Girardi G., Redecha P., Salmon JEHeparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med2004; 10: 1222-1226.
3.
Laskin CA, Spitzer KA, Clark CA et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol2009; (in press).
4.
Farquharson RG, Quenby S., Greaves M.Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol2002; 100: 408-413.
5.
Meyer GMZ , Valke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med2002; 162: 1729-1735.
6.
Siragusa S.Low molecular weight heparins as antineoplastic agents. Recent Pat Anticancer Drug Discov2008; 3: 159-161.
7.
Nelson-Piercy C., Letsky EA, de Swiet M.Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol1997; 176: 1062-1068.
8.
Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol1994; 170: 862-869.
9.
Dahlman TC, Sjoberg HE, Ringertz H.Bone mineral density during long-term prophylaxis with heparin in pregnancy . Am J Obstet Gynecol1994; 170: 1315-1320.
10.
Ruiz-Irastorza G., Khamashta MA, Hughes GRHeparin and osteoporosis during pregnancy: 2002 update. Lupus2002; 11: 680-682.
11.
Sambrook P. , Cooper C.Osteoporosis. Lancet2006; 367: 2010-2018.
12.
Reid DMHow valid is it to conclude that long-term heparin use is not associated with osteoporosis?J Thromb Haemost2007; 5: 1598-1599.
13.
Kanis JA, Johnell O., Oden A., et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int2001; 12: 989-995.
14.
Greenhalgh T.Papers that summarise other papers (systematic reviews and meta-analyses). BMJ1997; 315: 672-675.
15.
Hunt BJ, Doughty HA, Majumdar G., et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost1997 ; 77: 39-43.
16.
Byrd L.M., Shiach C.R., Hay C.R.M., Johnston T.A.Osteopenic fractures in pregnancy: Is low molecular weight heparin (LMWH) implicated?Journal of Obstetrics & Gynaecology2008; 28, 539-542.
17.
Goeb V., Strotz V., Verdet M., Le Loet X., Vittecoq O.Post-partum sacral fracture associated with heparin treatment. Clin Rheumatol2008; 27(Suppl 2): S51-S53.
18.
Breuil V., Brocq O., Euller-Ziegler L., Grimaud A.Insufficiency fracture of the sacrum revealing a pregnancy associated osteoporosis. First case report. Ann Rheum Dis1997; 56: 278-279.
19.
Sivakumaran M., Ghosh K., Zaidi Y., Hutchinson RMOsteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. Clin Lab Haematol1996 ; 18: 55-57.
20.
Monreal M., Vinas L., Monreal L., et al. Heparin-related osteoporosis in rats.A comparative study between unfractioned heparin and a low-molecular-weight heparin. Haemostasis1990; 20: 204-207.
21.
Greer IA, Nelson-Piercy C.Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood2005; 106: 401-407.
22.
Ensom MH, Stephenson MDLow-molecular-weight heparins in pregnancy. Pharmacotherapy1999; 19: 1013-1025.
23.
Casele H., Haney EI, James A., Rosene-Montella K., Carson M.Bone density changes in women who receive thromboprophylaxis in pregnancy . Am J Obstet Gynecol2006; 195: 1109-1113.
24.
Pettila V., Leinonen P., Markkola A., Hiilesmaa V., Kaaja R.Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost2002; 87: 182-186.
25.
Wawrzynska L., Tomkowski WZ, Przedlacki J., Hajduk B., Torbicki A.Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb2003; 33: 64-67.
26.
Lepercq J., Conard J.,Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG2001; 108: 1134-1140.
27.
Huxtable LM , Tafreshi MJ, Ondreyco SMA protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies . Clin Appl Thromb Hemost2005; 11: 171-181.
28.
Casele HL, Laifer SAProspective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med2000; 9: 122-125.
29.
Melissari E. , Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost1992; 68: 652-656.
30.
Carlin AJ, Farquharson RG, Quenby SM, Topping J., Fraser WDProspective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod2004; 19: 1211-1214.
31.
Rodger MA, Kahn SR, Cranney A., et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost2007; 5: 1600-1606.
32.
Ginsberg JS , Hirsh J.Use of antithrombotic agents during pregnancy . Chest1998; 114: 524S-530S.
33.
Hirsh J., Warkentin TE, Raschke R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety . Chest1998; 114: 489S-510S.
34.
Schulman S. , Hellgren-Wangdahl M.Pregnancy, heparin and osteoporosis. Thromb Haemost2002; 87: 180-181.
35.
Hurley MM, Kream BE, Raisz LGStructural determinants of the capacity of heparin to inhibit collagen synthesis in 21-day fetal rat calvariae. J Bone Miner Res1990; 5: 1127-1133.
36.
Muir JM, Hirsh J., Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood1997; 89: 3236-3242.
37.
Handschin AE , Trentz OA, Hoerstrup SP, et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg2005; 92: 177-183.
38.
Vik A., Brodin E., Sveinbjornsson B., Hansen JBHeparin induces mobilization of osteoprotegerin into the circulation . Thromb Haemost2007; 98: 148-154.
39.
Hofbauer LC , Khosla S., Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res2000; 15: 2-12.
40.
Hampson G., Martin FC, Moffat K., et al. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. Osteoporos Int2003; 14: 750-756.
41.
Handschin AE , Egermann M., Trentz O., et al. Cbfa-1 (Runx-2) and osteocalcin expression by human osteoblasts in heparin osteoporosis in vitro. Clin Appl Thromb Hemost2006; 12: 465-472.
42.
Ruiz-Irastorza G., Khamashta MA, Nelson-Piercy C., Hughes GRLupus pregnancy: is heparin a risk factor for osteoporosis?Lupus2001; 10: 597-600.
43.
Fiore CE, Pennisi P., DiStefano A., Riccobene S., Caschetto S.Pregnancy-associated changes in bone density and bone turnover in the physiological state: prospective data on sixteen women. Horm Metab Res2003; 35: 313-318.
44.
Karlsson C. , Obrant KJ, Karlsson M.Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int2001; 12: 828-834.
45.
Black AJ, Topping J., Durham B., Farquharson RG, Fraser WDA detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res2000; 15: 557-563.
46.
More C, Bettembuk P., Bhattoa HP, Balogh A.The effects of pregnancy and lactation on bone mineral density. Osteoporosis Intern2001; 12: 732-737.
47.
Morrison NA , Qi JC, Tokita A., et al. Prediction of bone density from vitamin D receptor alleles. Nature1994; 367: 284-287.
48.
Kurabayashi T., Tomita M., Matsushita H., et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol1999; 180: 1115-1120.
49.
Palomba S., Numis FG, Mossetti G., et al. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod2003; 18: 192-198.
50.
Kobayashi S. , Inoue S., Hosoi T., Ouchi Y., Shiraki M., Orimo H.Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res1996; 11: 306-311.
51.
Salmén T., Heikkinen A., Mahonen A., et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res2000; 15: 315-321.
52.
Ioannidis JPA , Stavrou I., Trikalinos TA, et al. Association of polymorphisms of the estrogen receptor α gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res2002 ; 17: 2048-2060.
53.
Matsushita H., Kurabayashi T., Tomita M., Tanaka K.Effects of vitamin D and estrogen receptor gene polymorphisms on the changes in lumbar bone mineral density with multiple pregnancies in Japanese women. Human Reproduction2004; 19: 59-64.
54.
Nordin BE, Roper A. Post-pregnancy osteoporosis; a syndrome? Lancet 1955; 268: 431-434.
55.
Smith R., Athanasou NA, Ostlere SJ, Vipond SEPregnancy-associated osteoporosis. QJM1995 ; 88: 865-878.
56.
Stumpf UC, Kurth AA, Windolf J., Fassbender WJPregnancy-associated osteoporosis: an underestimated and under-diagnosed severe disease. A review of two cases in short- and long-term follow-up. Adv Med Sci2007; 52: 94-97.
